Certara, Inc. (NASDAQ:CERT) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Certara, Inc. (NASDAQ:CERT) have received an average rating of “Hold” from the nine ratings firms that are covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $17.79.

A number of research analysts recently commented on CERT shares. Robert W. Baird decreased their price objective on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. KeyCorp cut their price objective on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. UBS Group decreased their target price on shares of Certara from $20.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. JMP Securities reissued a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Finally, Barclays lowered their price objective on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, June 28th.

Insider Buying and Selling at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.39% of the stock is currently owned by corporate insiders.

Institutional Trading of Certara

A number of large investors have recently made changes to their positions in CERT. Mubadala Investment Co PJSC acquired a new position in Certara during the 4th quarter worth approximately $169,135,000. Franklin Resources Inc. increased its holdings in Certara by 8.2% in the fourth quarter. Franklin Resources Inc. now owns 1,820,864 shares of the company’s stock valued at $32,029,000 after buying an additional 138,682 shares during the last quarter. Sei Investments Co. lifted its holdings in Certara by 12.4% during the 1st quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock worth $12,793,000 after buying an additional 79,013 shares during the last quarter. Edmond DE Rothschild Holding S.A. boosted its position in shares of Certara by 93.1% during the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 769,300 shares of the company’s stock worth $13,532,000 after acquiring an additional 370,820 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Certara during the 4th quarter worth about $14,262,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Trading Down 3.6 %

CERT opened at $10.90 on Friday. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -27.95, a price-to-earnings-growth ratio of 5.23 and a beta of 1.49. The company’s 50 day simple moving average is $13.26 and its two-hundred day simple moving average is $15.40. Certara has a 1-year low of $10.35 and a 1-year high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The company had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. During the same period last year, the firm posted $0.10 EPS. The business’s quarterly revenue was up 3.2% on a year-over-year basis. Analysts expect that Certara will post 0.27 EPS for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.